Edition:
United States

Ovid Therapeutics Inc (OVID.OQ)

OVID.OQ on NASDAQ Stock Exchange Global Select Market

7.04USD
16 Feb 2018
Change (% chg)

$0.01 (+0.14%)
Prev Close
$7.03
Open
$7.16
Day's High
$7.59
Day's Low
$6.95
Volume
18,548
Avg. Vol
19,953
52-wk High
$15.70
52-wk Low
$5.28

Select another date:

Wed, Dec 20 2017

BRIEF-Ovid Therapeutics Announces TAK-935/OV935 Granted Orphan Drug Designation By U.S. FDA For Treatment Of Lennox-Gastaut Syndrome

* OVID THERAPEUTICS ANNOUNCES TAK-935/OV935 GRANTED ORPHAN DRUG DESIGNATION BY U.S. FDA FOR TREATMENT OF LENNOX-GASTAUT SYNDROME

BRIEF-Ovid Therapeutics Announces OV101 Granted Fast Track Designation By U.S. FDA For Treatment Of Angelman Syndrome

* OVID THERAPEUTICS ANNOUNCES OV101 GRANTED FAST TRACK DESIGNATION BY U.S. FDA FOR TREATMENT OF ANGELMAN SYNDROME

BRIEF-Ovid Therapeutics Announces TAK-935/Ov935 Has Received Orphan Drug Designation From U.S. FDA For Treatment Of Dravet Syndrome

* OVID THERAPEUTICS ANNOUNCES TAK-935/OV935 HAS RECEIVED ORPHAN DRUG DESIGNATION FROM U.S. FDA FOR TREATMENT OF DRAVET SYNDROME

BRIEF-Ovid Therapeutics Announces OV101 Shows Comparable Pk Profile In Phase 1 Study Of Adolescent Patients

* OVID THERAPEUTICS ANNOUNCES OV101 SHOWS COMPARABLE PK PROFILE IN PHASE 1 STUDY OF ADOLESCENT PATIENTS AND AMENDS PHASE 2 STARS CLINICAL TRIAL PROTOCOL TO INCLUDE ADOLESCENTS

BRIEF-Ovid Therapeutics Q3 loss per share $0.38

* Ovid Therapeutics reports third quarter 2017 financial results and corporate progress

BRIEF-Ovid Therapeutics announces first patient randomized in phase 1b/2a clinical trial of TAK-935

* Ovid Therapeutics announces first patient randomized in phase 1b/2a clinical trial of TAK-935/OV935 in adults with rare epilepsies Source text for Eikon: Further company coverage:

Select another date: